Phase II study of weekly docetaxel combined with cisplatin in patients with advanced non-small-cell lung cancer

Cancer Chemotherapy and Pharmacology

Volumn 54, Issue 2, 2004, Pages 173-177

  Tsunoda, Toshiyuki ^a   Koizumi, Tomonobu ^a   Hayasaka, Muneharu ^a   Hirai, Kazuya ^a   Koyama, Shigeru ^a   Takabayashi, Yasuki ^a   Fujimoto, Keisaku ^a   Kubo, Keishi ^a  

^a SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Cisplatin; Neurotoxicity; Neutropenia; Non small cell lung cancer; Weekly docetaxel

Indexed keywords

ANTIEMETIC AGENT; ANTIINFECTIVE AGENT; CISPLATIN; DOCETAXEL; ONDANSETRON; PROCHLORPERAZINE;

AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; ASTHENIA; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE COURSE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG RESPONSE; DRUG SAFETY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPONATREMIA; LEUKOPENIA; LIVER TOXICITY; LUNG NON SMALL CELL CANCER; MALE; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PHYSICAL EXAMINATION; PRIORITY JOURNAL; SIDE EFFECT; SURVIVAL RATE; THROMBOCYTOPENIA; TIME SERIES ANALYSIS; VOMITING;

EID: 3843134085     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-004-0810-5     Document Type: Article

References (24)

1. Aihara T, Kim Y, Takatsuka Y (2002) Phase II of weekly docetaxel in patients with metastatic breast cancer. Ann Oncol 13:286-292
2. Belani CP, Barstis J, Perry MC, La Rocca RV, Nattam SR, Rinaldi D, Clark R, Mills GM (2003) Multicenter, randomized trial for stage IIIB or IV non-small-cell lung cancer using weekly paclitaxel and carboplatin followed by maintenance weekly paclitaxel or observation. J Clin Oncol 21:2933-2939
3. Burstein HJ, Manola J, Younger J, Parker LM, Bunnell CA, Scheib R, Matulonis UA, Garber JE, Clarke KD, Shulman LN, Winer EP (2000) Docetaxel administration on a weekly basis for metastatic breast cancer. J Clin Oncol 18:1212-1219
4. Francis PA, Rigas JR, Kris MG, Pisters KM, Orazem JP, Woolley KJ, Heelan RT (1994) Phase II trial of docetaxel in patients with stage III and IV non-small-cell lung cancer. J Clin Oncol 12:1232-1237
5. Gandara DR, Vokes E, Green M, Bonomi P, Devore R, Comis R, Carbone D, Karp D, Belani C (2000) Activity of docetaxel in platinum-treated non-small-cell lung cancer: results of a phase II multicenter trial. J Clin Oncol 18:131-135
6. Hainsworth JD, Burris HA III, Thomas EM, Greco FA (1998) Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer. J Clin Oncol 16:2164-2168
7. Hilkens PHE, Pronk LC, Verweij J, Vecht CJ, van Putten WLJ, van den Bent MJ (1997) Peripheral neuropathy induced by combination chemotherapy of docetaxel and cisplatin. Br J Cancer 75:417-422
8. Kelland LR, Abel G (1992) Comparative in vitro cytotoxicity of taxol and taxotere against cisplatin-sensitive and -resistant human ovarian carcinoma cell lines. Cancer Chemother Pharmacol 30:444-450
9. Koizumi T, Tsunoda T, Fujimoto K, Nomura H, Hirai K, Koyama S, Okada K, Kubo K (2001) Phase I trial of weekly docetaxel combined with cisplatin in patients with non-small-cell lung cancer. Lung Cancer 34:125-131
10. Koukourakis MI, Kourousis C, Kamilaki M, Koukouraki S, Giatromanolaki A, Kakolyris S, Kotsakis A, Androulakis N, Bahlitzanakis N, Georgoulias V (1998) Weekly docetaxel and concomitant boost radiotherapy for non-small cell lung cancer. A phase I/II dose escalation trial. Eur J Cancer 34:838-844
11. Kubota K, Watanabe K, Kunitoh H, Noda K, Ichinose Y, Katakami N, Sugiura T, Kawahara M, Yokoyama A, Yokota S, Yoneda S, Matsui K, Kudo S, Shibuya M, Isobe T, Segawa Y, Nishiwaki Y, Ohashi Y, Niitani H; Japanese Taxotere Lung Cancer Study Group (2004) Phase III randomized trial of docetaxel plus cisplatin versus vindesine plus cisplatin in patients with stage IV non-small-cell lung cancer: the Japanese Taxotere Lung Cancer Study Group. J Clin Oncol 22:254-261
12. Le Chevalier T, Monnier A, Douillard JY, Ruffie P, Sun XS, Belli L, Ibrahim N, Bougon N, Berille J (1998) Docetaxel (Taxotere) plus cisplatin: an active and well-tolerated combination in patients with advanced non-small cell lung cancer. Eur J Cancer 34:2032-2036
13. Miller AB, Hoogstraten B, Staquet M, Winkler A (1981) Reporting results of cancer treatment. Cancer 47:207-214
14. 2 dose of docetaxel with prednisone premedication for patients with advanced non-small cell lung cancer. Cancer 75:968-972
15. Millward MJ, Zalcberg J, Bishop JF, Webster LK, Zimet A, Rischin D, Toner GC, Laird J, Cosolo W, Urch M, Bruno R, Loret C, James R, Blanc C (1997) Phase I trial of docetaxel and cisplatin in previously untreated patients with advanced non-small-cell lung cancer. J Clin Oncol 15:750-758
16. Mudad R, Ramsey M, Kovitz K, Curiel T, Curiel TJ, Hartz R, Nedzi LL, Weiner RS, Zakris EL (2003) Concomitant weekly docetaxel, cisplatin and radiotherapy in locally advanced non-small cell lung cancer: a dose finding study. Lung Cancer 39:173-177
17. Niho S, Ohe Y, Kakinuma R, Kubota K, Matsumoto T, Ohmatsu H, Goto K, Nishiwaki Y (2002) Phase II study of docetaxel and cisplatin administered as three consecutive weekly infusions for advanced non-small cell lung cancer. Lung Cancer 35:209-214
18. Ohe Y, Niho S, Kakinuma R, Kubota K, Matsumoto T, Ohmatsu H, Goto K, Kunitoh H, Saijo N, Nishiwaki Y (2001) Phase I studies of cisplatin and docetaxel administered by three consecutive weekly infusions for advanced non-small cell lung cancer in elderly and non-elderly patients. Jpn J Clin Oncol 31:100-106
19. Okamoto H, Watanabe K, Segawa Y, Ichinose Y, Yokoyama A, Yoneda S, Mitani H (2000) Phase II study of docetaxel and cisplatin in patients with previous untreated metastatic non-small cell lung cancer. Int J Clin Oncol 5:316-322
20. Onishi H, Kuriyama K, Yamaguchi M, Komiyama T, Tanaka S, Araki T, Nishikawa K, Ishihara H (2003) Concurrent two-dimensional radiotherapy and weekly docetaxel in the treatment of stage III non-small cell lung cancer: a good local response but no good survival due to radiation pneumonitis. Lung Cancer 40:79-84
21. Ringer I, Horwitz SB (1991) Studies with RP 56976 (Taxotere): a semi-synthetic analog of taxol. J Natl Cancer Inst 83:288-291
22. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J, Johnson DH, Eastern Cooperative Oncology Group (2002) Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346:92-98
23. Tishler RB, Schiff PB, Geard CR, Hall EJ (1992) Taxol: a novel radiation sensitization. Int J Radiat Oncol Biol Phys 22:613-617
24. Zalcberg J, Millward MJ, Bishop J, McKeage M, Zimet A, Toner G, Friedlander M, Barter C, Rischin D, Loret C, James R, Bougan N, Berille J (1998) Phase II study of docetaxel and cisplatin in advanced non-small-cell lung cancer. J Clin Oncol 16:1948-1953